Previous close | 2.3400 |
Open | 2.3100 |
Bid | 2.0900 x 100 |
Ask | 2.2100 x 100 |
Day's range | 2.0000 - 2.3100 |
52-week range | 2.0000 - 44.8000 |
Volume | |
Avg. volume | 1,472,555 |
Market cap | 3.35M |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Discover how Bio-Path Holdings Inc navigates improved clinical outcomes and financial maneuvers in the first quarter of 2024.
Q1 2024 Bio Path Holdings Inc Earnings Call
Bio-Path (BPTH) gains 30% on encouraging developmental updates from the early-stage study of its investigational candidate, BP1002, to treat acute myeloid leukemia patients.